Coronary Artery DiseaseTemporal Trends in the Occurrence and Outcomes of Atrial Fibrillation in Patients With Acute Myocardial Infarction (from the Atherosclerosis Risk in Communities Surveillance Study)
Section snippets
Methods
The community surveillance component of the Atherosclerosis Risk in Communities (ARIC) Study, described previously, was designed to provide knowledge about the burden of and trends in coronary heart disease (CHD) morbidity and mortality in 4 US communities (details included in the Supplementary Material).9, 10
Presence of AF during the MI hospitalization was defined by the presence of AF International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), hospital
Results
Our final analytic sample included 13,155 definite and probable first-incident MIs, for a weighted sample of 20,049. Baseline patient characteristics over time, in 4-year intervals, are listed in Table 1, whereas Table 2 lists the prevalence of medications and therapeutic procedures. The age and sex distributions of the sample were stable over the study period, with an overall mean age of 59 years at the time of hospitalization; women accounted for 36% of the sample. The prevalence of AF
Discussion
In this population-based sample of validated MI hospitalizations, the prevalence of concomitant AF in MI increased slightly from 1987 to 2009 and was approximately 15% in the most recent years. The secular trend in the prevalence of AF in the setting of MI differed by MI classification; the prevalence of coexisting AF increased over time among NSTEMI and unclassified MIs and decreased among STEMIs. Co-occurrence of AF in the setting of MI was associated with an increased risk of death, and this
Disclosures
The authors have no conflicts of interest to disclose.
References (28)
- et al.
Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI
Am J Med
(2011) - et al.
Trends in atrial fibrillation complicating acute myocardial infarction
Am J Cardiol
(2009) - et al.
Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study
Am Heart J
(2009) - et al.
Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience
J Clin Epidemiol
(1996) - et al.
Fourteen-year (1987 to 2000) trends in the attack rates of, therapy for, and mortality from non-ST-elevation acute coronary syndromes in four United States communities
Am J Cardiol
(2005) - et al.
Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006
Am Heart J
(2008) - et al.
Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987–2008
Circulation
(2012) - et al.
Trends in incidence, severity, and outcome of hospitalized myocardial infarction
Circulation
(2010) - et al.
Heart disease and stroke statistics—2013 update: a report from the American Heart Association
Circulation
(2013) - et al.
Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis
Circulation
(2011)
Atrial fibrillation and death after myocardial infarction: a community study
Circulation
The atherosclerosis risk in communities (ARIC) study: design and objectives. The ARIC Investigators
Am J Epidemiol
A systematic review of validated methods for identifying atrial fibrillation using administrative data
Pharmacoepidemiol Drug Saf
PREDICT: a simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: the Minnesota Heart Survey
Circulation
Cited by (0)
The Atherosclerosis Risk in Communities Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C. This study additionally was supported by the National Heart, Lung, and Blood Institute grants RC1-HL-099452 and T32-HL-07779 (to Bengtson) and the American Heart Association grant 09SDG2280087.
See page 696 for disclosure information.